Chemours CC Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.82B+0.2% | $5.81B-0.5% | $5.84B-0.2% | $5.85B+1.1% | $5.79B+0.1% | ||
| $4.94B+0.8% | $4.91B+1.7% | $4.83B+0.8% | $4.79B+1.9% | $4.69B+1.2% | ||
| $878M-2.7% | $902M-10.9% | $1.01B-5.0% | $1.07B-2.7% | $1.1B-4.2% | ||
| 15.1%-0.4pp | 15.5%-1.8pp | 17.3%-0.9pp | 18.2%-0.7pp | 18.9%-0.8pp | ||
| $107M-0.9% | $108M+0.9% | $107M-2.7% | $110M+1.9% | $108M-0.9% | ||
| $823M+3.0% | $799M-4.8% | $839M-1.8% | $854M+46.2% | $584M-2.3% | ||
| $969M+0.3% | $966M-4.3% | $1.01B-10.2% | $1.12B+34.3% | $837M+1.7% | ||
| $272M+1.1% | $269M+0.4% | $268M0.0% | $268M+0.4% | $267M+1.1% | ||
| $43M+65.4% | $26M— | —— | —— | —— | ||
| -$299M-7.9% | -$277M-32.5% | -$209M+25.1% | -$279M-834% | $38M-64.8% | ||
| —— | —— | $140M-5.4% | $148M+469% | $26M-29.7% | ||
| -$410M-6.2% | -$386M-10.3% | -$350M+18.2% | -$428M-3,667% | $12M-83.1% | ||
| -7%-0.4pp | -6.6%-0.7pp | -6%+1.3pp | -7.3%-7.5pp | 0.2%-1.0pp | ||
| -$2.72-6.3% | -$2.56-9.9% | -$2.33+18.5% | -$2.86-4,867% | $0.06-86.7% | ||
| $304M-8.4% | $332M-15.3% | $392M+24.4% | $315M-48.7% | $614M-7.5% | ||
| 5.2%-0.5pp | 5.7%-1.0pp | 6.7%+1.3pp | 5.4%-5.2pp | 10.6%-0.9pp | ||
| -$27M-238% | -$8M-114% | $59M+636% | -$11M-104% | $305M-18.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Chemours's income statement data come from?
- Every line is extracted from Chemours's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.